1st stage of Vaccine trails successful for COVID-19:

#GS3#Science and Technology#

  • The AZD1222 vaccine is based on a chimpanzee adenovirus and is called ChAdOx1
  • The early-stage human trial data of a COVID-19 vaccine developed by AstraZeneca and Oxford University reveals that it is safe and induces an immune response, with mild side effects in some participants.   
  • The preliminary results of phase I/II trial, published in The Lancet journal, involving 1107 people show that the injection led to them making antibodies and T-cells that can fight coronavirus.
  • The study showed 90 percent of involved people developed neutralizing antibodies after one dose. Only ten people were given two doses and all of them produced neutralizing antibodies.

 

Background:

  • Oxford’s AZD1222 vaccine is made from a genetically engineered virus that causes the common cold in chimpanzees. However, the virus has been modified so that it doesn’t cause infection in people and also to mimic the coronavirus.
  • Scientists did this by transferring the genetic instructions of the coronavirus’ “spike protein” – the crucial tool it uses to invade human cells – to the vaccine. This was done so that the vaccine resembles the coronavirus and the immune system can learn how to attack it.

 

Side Effects: 

  • The experimental COVID­19 vaccine caused minor side effects like fever, chills, and muscle pain more often than in those who got a control meningitis vaccine.
Print Friendly and PDF

Previous   Next

blog comments powered by Disqus